Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia

@article{Bug2005ClinicalTO,
  title={Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia},
  author={G. Bug and M. Ritter and B. Wassmann and C. Schoch and T. Heinzel and K. Schwarz and A. Romanski and Oliver H Kramer and M. Kampfmann and D. Hoelzer and A. Neubauer and M. Ruthardt and O. Ottmann},
  journal={Cancer},
  year={2005},
  volume={104}
}
  • G. Bug, M. Ritter, +10 authors O. Ottmann
  • Published 2005
  • Medicine
  • Cancer
  • Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary acute myeloid leukemia (AML) blasts, an effect enhanced by all‐trans retinoic acid (ATRA). Clinical responses to VPA were recently observed in patients with myelodysplastic syndrome (MDS). Herein, the authors have described results of a clinical trial with VPA plus ATRA in 26 patients with poor‐risk AML. 
    176 Citations
    Valproic acid for the treatment of myeloid malignancies
    • 52
    • Highly Influenced
    An ATRActive future for differentiation therapy in AML.
    • 33
    The Activity of Valproic Acid in the Treatment of Refractory Hyperleukocytosis in a Child with Acute Lymphoblastic Leukemia
    • 1
    Elevated FOSB‐expression; a potential marker of valproate sensitivity in AML
    • 18

    References

    SHOWING 1-10 OF 29 REFERENCES
    Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
    • 1,615
    • Highly Influential
    • PDF
    Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
    • 535
    • Highly Influential
    • PDF
    International scoring system for evaluating prognosis in myelodysplastic syndromes.
    • 3,864
    • PDF